

Eric S Kilpatrick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11309307/publications.pdf>

Version: 2024-02-01

49
papers

2,923
citations

201674

27
h-index

197818

49
g-index

49
all docs

49
docs citations

49
times ranked

3529
citing authors

#	ARTICLE	IF	CITATIONS
1	Progressive loss of corneal nerve fibers is associated with physical inactivity and glucose lowering medication associated with weight gain in type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1703-1710.	2.4	6
2	The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome. <i>Endocrine Connections</i> , 2020, 9, 563-569.	1.9	15
3	Relationship between a single measurement at baseline of body mass index, glycated hemoglobin, and the risk of mortality and cardiovascular morbidity in type 2 diabetes mellitus. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 177-182.	1.1	5
4	A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome. <i>Nutrients</i> , 2019, 11, 188.	4.1	61
5	The Effects of Soy Protein and Cocoa With or Without Isoflavones on Glycemic Control in Type 2 Diabetes. A Double-Blind, Randomized, Placebo-Controlled Study. <i>Frontiers in Endocrinology</i> , 2019, 10, 296.	3.5	22
6	Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. <i>Clinical Endocrinology</i> , 2019, 90, 805-813.	2.4	68
7	Development of a novel risk prediction and risk stratification score for polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2019, 90, 162-169.	2.4	13
8	Prediabetes and diabetes in a cohort of Qatari women screened for polycystic ovary syndrome. <i>Scientific Reports</i> , 2018, 8, 3619.	3.3	17
9	The Effect of High Dose Isoflavone Supplementation on Serum Reverse T3 in Euthyroid Men With Type 2 Diabetes and Post-menopausal Women. <i>Frontiers in Endocrinology</i> , 2018, 9, 698.	3.5	9
10	Dynamic Change in Insulin Resistance Induced by Free Fatty Acids Is Unchanged Though Insulin Sensitivity Improves Following Endurance Exercise in PCOS. <i>Frontiers in Endocrinology</i> , 2018, 9, 592.	3.5	11
11	The Effect of Phytoestrogen on Thyroid in Subclinical Hypothyroidism: Randomized, Double Blind, Crossover Study. <i>Frontiers in Endocrinology</i> , 2018, 9, 531.	3.5	12
12	Effect of Soy in Men With Type 2 Diabetes Mellitus and Subclinical Hypogonadism – A Randomized Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2875.	3.6	35
13	A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 255-264.	4.4	24
14	The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome. <i>Endocrine Connections</i> , 2017, 6, 811-816.	1.9	5
15	Salivary testosterone measurement in women with and without polycystic ovary syndrome. <i>Scientific Reports</i> , 2017, 7, 3589.	3.3	10
16	Soy Reduces Bone Turnover Markers in Women During Early Menopause: A Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 157-164.	2.8	45
17	Soy Protein Improves Cardiovascular Risk in Subclinical Hypothyroidism: A Randomized Double-Blinded Crossover Study. <i>Journal of the Endocrine Society</i> , 2017, 1, 423-430.	0.2	10
18	Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. <i>BMC Endocrine Disorders</i> , 2017, 17, 41.	2.2	6

#	ARTICLE	IF	CITATIONS
19	The prevalence and metabolic characteristics of polycystic ovary syndrome in the Qatari population. PLoS ONE, 2017, 12, e0181467.	2.5	31
20	Current Evidence and Future Perspectives on the Effective Practice of Patient-Centered Laboratory Medicine. Clinical Chemistry, 2015, 61, 589-599.	3.2	61
21	Glycemic Variability: Both Sides of the Story. Diabetes Care, 2013, 36, S272-S275.	8.6	91
22	Glycemic Control in the 12 Months following a Change to SI Hemoglobin A1c Reporting Units. Clinical Chemistry, 2013, 59, 1457-1460.	3.2	6
23	A reversible rise in the total cholesterol to HDL ratio in a body builder. British Journal of Diabetes and Vascular Disease, 2012, 12, 200-202.	0.6	1
24	Atorvastatin Reduces Malondialdehyde Concentrations in Patients with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3951-3955.	3.6	30
25	Using Multiple Measures of Glycemia to Support Individualized Diabetes Management: Recommendations for Clinicians, Patients, and Payers. Diabetes Technology and Therapeutics, 2012, 14, 973-983.	4.4	16
26	Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. Annals of Clinical Biochemistry, 2012, 49, 80-85.	1.6	29
27	The Effect of Soy Phytoestrogen Supplementation on Thyroid Status and Cardiovascular Risk Markers in Patients with Subclinical Hypothyroidism: A Randomized, Double-Blind, Crossover Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1442-1449.	3.6	81
28	A national survey of interpretative reporting in the UK. Annals of Clinical Biochemistry, 2011, 48, 317-320.	1.6	28
29	A national audit of estimated glomerular filtration rate and proteinuria reporting in the UK. Annals of Clinical Biochemistry, 2011, 48, 558-561.	1.6	12
30	Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS). Clinical Endocrinology, 2010, 72, 566-568.	2.4	30
31	The Role of Blood Pressure Variability in the Development of Nephropathy in Type 1 Diabetes. Diabetes Care, 2010, 33, 2442-2447.	8.6	74
32	Atorvastatin Increases 25-Hydroxy Vitamin D Concentrations in Patients with Polycystic Ovary Syndrome. Clinical Chemistry, 2010, 56, 1696-1700.	3.2	48
33	The hitchhiker's guide to research in clinical biochemistry. Clinical Biochemist Reviews, 2010, 31, 25-8.	3.3	3
34	The Effect of Atorvastatin in Patients with Polycystic Ovary Syndrome: A Randomized Double-Blind Placebo-Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 103-108.	3.6	129
35	Effect of Glucose Variability on the Long-Term Risk of Microvascular Complications in Type 1 Diabetes. Diabetes Care, 2009, 32, 1901-1903.	8.6	124
36	Arguments for and against the Role of Glucose Variability in the Development of Diabetes Complications. Journal of Diabetes Science and Technology, 2009, 3, 649-655.	2.2	29

#	ARTICLE	IF	CITATIONS
37	Appropriate requesting of serum tumour markers. <i>BMJ, The</i> , 2009, 339, b3111-b3111.	6.0	28
38	The Diabetes Control and Complications Trial: the gift that keeps giving. <i>Nature Reviews Endocrinology</i> , 2009, 5, 537-545.	9.6	46
39	Alterations in thyroid status do not affect plasma peptide YY (PYY) and ghrelin concentrations. <i>Clinical Endocrinology</i> , 2008, 68, 836-838.	2.4	6
40	A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes. <i>Diabetes Care</i> , 2008, 31, 2198-2202.	8.6	377
41	Variability in the Relationship between Mean Plasma Glucose and HbA1c: Implications for the Assessment of Glycemic Control. <i>Clinical Chemistry</i> , 2007, 53, 897-901.	3.2	85
42	Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes: "Double diabetes" in the Diabetes Control and Complications Trial. <i>Diabetes Care</i> , 2007, 30, 707-712.	8.6	347
43	Effects of Isoflavone Dietary Supplementation on Cardiovascular Risk Factors in Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 1871-1873.	8.6	59
44	The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes. <i>Diabetes Care</i> , 2006, 29, 1486-1490.	8.6	317
45	The effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide concentrations. <i>Annals of Clinical Biochemistry</i> , 2006, 43, 184-188.	1.6	5
46	Hypopituitarism presenting as a mixed hyperlipidaemia. <i>Annals of Clinical Biochemistry</i> , 2004, 41, 344-345.	1.6	1
47	Paradoxical Changes in Cystatin C and Serum Creatinine in Patients with Hypo- and Hyperthyroidism. <i>Clinical Chemistry</i> , 2003, 49, 680-681.	3.2	88
48	Beneficial Effects of Soy Phytoestrogen Intake in Postmenopausal Women With Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 1709-1714.	8.6	308
49	Use of computer terminals on wards to access emergency test results: a retrospective audit. <i>BMJ: British Medical Journal</i> , 2001, 322, 1101-1103.	2.3	59